This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joan Stephenson, PhD

JAMA. 2001;286:1704.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A rare mutation discovered linked to early-onset Alzheimer disease (AD) points to a new pathogenic mechanism for the disease and suggests a new target for treating the disease, according to research reported in the September issue of Nature Neuroscience.

Scientists previously identified mutations in the amyloid precursor protein (APP) gene linked to early-onset disease, mutations that result in increased production of amyloid -protein (A), a component of the amyloid plaques in the brains of people with AD. However, in the new work, researchers from the Karolinska Institute, in Huddinge, Sweden, and collaborators discovered a mutation in members of an AD-prone family from northern Sweden that results in low levels of A but allows the formation of higher levels of protofibrils, small protein complexes that are an intermediate step in the formation of amyloid plaques. This discovery "may reflect an alternative pathogenic mechanism for AD involving . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?